Cure My Disease

Don't miss your cure!

 Log in / Sign up

New drug combo aims to slow advanced breast cancer

NCT ID NCT07285382

Recruiting now Disease control Sponsor: wanghaibo Source: ClinicalTrials.gov ↗

First seen Dec 29, 2025 · Last updated May 15, 2026 · Updated 21 times

Summary

This study tests two different doses of the drug dalpiciclib combined with letrozole in 120 women with a specific type of advanced breast cancer (HR-positive, HER2-negative). The goal is to see how long the cancer stays under control. Participants are randomly assigned to one of two dose groups and monitored for side effects and cancer progression.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HR-POSITIVE, HER2-NEGATIVE ADVANCED BREAST CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Qingdao University Affiliated Hospital

    RECRUITING

    Qingdao, Shandong, 266000, China

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • The Second Affiliated Hospital of Dalian Medical University

    RECRUITING

    Dalian, Liaoning, 116027, China

    Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.

HR-POSITIVE, HER2-NEGATIVE ADVANCED BREAST CANCER HR-POSITIVE, HER2-NEGATIVE ADVANCED BREAST CANCER HR-POSITIVE, HER2-NEGATIVE ADVANCED BREAST CANCER